enzyme linked immunosorbent assay elisa kit  (R&D Systems)

Journal: Advanced Science

Article Title: Aged ZnO Nanoparticles Promote Breast Cancer Lung Metastasis by Remodeling the Pulmonary Microenvironment Through the CXCL10/Wnt/β‐Catenin Axis

doi: 10.1002/advs.78249

Figure Lengend Snippet: CXCL10 is upregulated in both macrophages and fibroblasts responding to aged ZnO NPs exposure. (A) Heatmaps exhibited multiplex cytokine profiling of serum and BALF from IT (PBS/fresh NPs/aged NPs intratracheal instillation) and IT + IV (IT exposure followed by intravenous injection of 4T1 cells) models ( n = 3). (B–E) Concentrations of significantly dyregulated cytokines in serum and BALF from mice exposed to ZnO NPs (fresh or aged), with or without subsequent 4T1 cell injection ( n = 3). (F) Venn plot showed the overlapping cytokines in serum and BALF between IT and IT + IV models. (G) ELISA detection of CXCL10 concentrations in serum and BALF of IT and IT + IV groups ( n = 3). (H) qPCR analysis of CXCL10 mRNA in lung tissue, primary fibroblasts, and alveolar macrophages post‐IT, normalized to GAPDH ( n = 3). (I, J) UMAP visualization (I) and dot plot (J) displaying CXCL10 expression across annotated cell types. (K, L) UMAP visualization (K) and dot plot (L) displaying CXCL10 expression across myeloid cell types. (M) Representative images of invasion and migration assays of 4T1 cells stimulated with 50 or 100 ng/mL murine recombinant CXCL10 (rCXCL10) for 72 h ( n = 3). (N) Quantification of invasion and migration assays ( n = 3). All data were represented as the mean ± SD. P values were calculated by one‐way ANOVA followed by Tukey's test. * p < 0.05, ** p < 0.01 vs control group; # p < 0.05, ## p < 0.01 vs fresh NPs group.

Article Snippet: CXCL10 (IP‐10) levels were measured using a mouse ELISA kit (Elabscience, E‐EL‐M0021) following the manufacturer's instructions.

Techniques: Multiplex Assay, Profiling, Injection, Enzyme-linked Immunosorbent Assay, Analysis, Tissue, Expressing, Migration, Recombinant, Control

Journal: Cell Reports Medicine

Article Title: Histone methyl-transferase G9a inhibition boosts the efficacy of immune checkpoint inhibitors in experimental hepatocellular carcinoma

doi: 10.1016/j.xcrm.2026.102717

Figure Lengend Snippet: G9a inhibition potentiates the immunogenic effects of IFN-γ in HCC cells (A) Effect of CM272 and EZM8266 on IFN-γ-triggered CXCL10 production in murine (PM299L) and human (HuH7) HCC cells. Cells were treated with CM272 for 48 h or with CM272 for 24 h and then with IFN-γ (75 U/mL) for another 24 h or with IFN-γ alone for 24 h. PM299L were treated with 400 nM, and HuH7 received 1 μM of CM272 ( n = 3). For EZM8266, cells were pretreated for 48 h with EZM8266 (5 mM) and then with IFN-γ (75 U/mL) for another 24 h, as indicated. CXCL10 protein levels were measured by ELISA in cells’ conditioned media ( n = 3). (B) Effect of G9a inhibition with CM272 or EZM8266 on the expression of MHC class I complex protein (MHC-I) on the surface of PM299L cells. Cells were treated with IFN-γ and CM272 or EZM8266 as indicated in (A), and MHC-I levels were determined by FACS analysis ( n = 3). (C) ChIP analyses of H3K9me2 levels in the proximal promoter regions of CXCL10 and HLA-A genes in HuH7 cells treated with IFN-γ (75 U/mL) and CM272 (400 nM), as indicated in (A) ( n = 3). (D) Evaluation of the expression of transposable elements (TEs) and endogenous retroviral sequences (ERVs) by RNA-seq in NM53 murine HCC cells treated with IFN-γ, CM272, and their combination as indicated in (A). (E) Immunofluorescence analyses of dsRNA in PM299L HCC cells treated with CM272 (24 h) or EZM8266 (48 h). Representative images are shown. Scale bars, 10 μm. Right panel shows a control without primary antibody ( n = 3). Data are represented as mean ± SEM. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001. All the replicates represent biological replicates.

Article Snippet: CXCL9 and CXCL10 concentrations were measured in culture supernatants collected at the end of the incubation periods using commercial ELISA kits for mouse CXCL9 (DY492) and CXCL10 (DY466), both from R&D Systems, and an ELISA kit for human CXCL10 (550926) from BD Biosciences (Franklin Lanes, NJ, USA).

Techniques: Inhibition, Enzyme-linked Immunosorbent Assay, Expressing, Retroviral, RNA Sequencing, Immunofluorescence, Control